Universal Vision Biotechnology , Ltd. Receivables

Universal Vision Biotechnology , Ltd. (3218.TWO) currently reports a receivables of $510M as of June 2026. That compares with $540M in the prior-year period — down 4.8% year over year. Use the charts on this page to explore Universal Vision Biotechnology , Ltd.'s receivables history and peer comparisons.

Universal Vision Biotechnology , Ltd.'s receivables decreased from $540M to $510M — a 4.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Universal Vision Biotechnology , Ltd. reported $510M in receivables as of June 2026. That compares with $540M in the prior-year period — down 4.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $510M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Universal Vision Biotechnology , Ltd., and consider following 3218.TWO for alerts when major investors trade the stock.